Another study demonstrated that specific blockade of the CCR7 pathway by a specific protein hydrolysis-resistant TC6-D3 peptide significantly reduced lymph node tumor load, promoted primary tumor CD8+ T-cell infiltration, and enhanced lymph node anti-tumor immune response, which is expected to be a new option for the treatment of OSCC (107). This evidence concerns the gene CD8A and neoplasm.